Aktuellt
SENASTE
Redeye provides an update on Scandinavian ChemoTech following the Q3 2024 report. The cost control from the company continues to be solid, although sales came in slightly below our estimates. We comment on the activities in the quarter, including a new partnership with NMBU, and are encouraged by the company's current treatment volumes. We make a few minor estimate changes and maintain our fair value range.
LÄS MER
